The most notable reduction in fissures with the DSIP-CBBBP fusion peptide group highlights its potential efficacy in improving brain tissue morphology
If clinical trials continue to show the current results, retatrutide will likely become the most effective single medication for weight loss once approved

Tesamorelin Recommended for body recomposition Pros Has been shown to selectively reduce abdominal fat in patients with HIV Can also increase muscle area and strength Promising implications for cognitive and cardiovascular health No reported risk of immunogenicity Cons Studies so far have focused on patients with HIV May cause flu-like symptoms Usually administered by subcutaneous injection Prohibited by the World Anti-Doping Agency Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy excess abdominal lipid accumulation as a result of antiretroviral therapy its efficacy against which was evidenced in a 2010 clinical trial that demonstrated an 18% decrease in visceral fat in intervention subjects compared to placebo.11 Concerning muscle growth, a later study of HIV patients determined that tesamorelin was effective in increasing skeletal muscle area and density.28 Also, because visceral fat is associated with increased cardiovascular mortality, tesamorelin exhibits promise as a treatment for serious health conditions like heart disease and stroke.37 Although tesamorelin studies so far have understandably centered on patients with HIV, theory holds that the peptide should have the same effects on other users

Retatrutide does not currently hold MHRA approval and is not licensed for use in the UK outside of clinical trials
Once it enters your bloodstream, your body breaks it down at a steady rate, influenced by factors such as body size, liver function, and overall health